<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:387726796;
mso-list-template-ids:-735305166;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:480971344;
mso-list-template-ids:-1558390494;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1416127364;
mso-list-template-ids:-98542316;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1790319103;
mso-list-template-ids:-572876960;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-145.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFwPZ7Mjc$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-144.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVF2viYq0w$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These FOAs seek innovative research to optimize HIV prevention and care that is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral
and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged
to read current Notices of Special Interests from NIMH DAR for further information about the Division’s research priorities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 7, 2020 standard date: April 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.michaeljfox.org/grant/investigating-environmental-factors-increase-risk-parkinsons-disease__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFirfSL2I$" target="_blank">Michael J. Fox Foundation: Investigating Environmental
Factors that Increase the Risk for Parkinson’s Disease</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">While some evidence links environmental factors with increased risk of PD, according to the foundation much remains unknown regarding the specific environmental risks, their role in disease,
and the quantification of their contributions. A better understanding of environmental risk factors for PD could lead to efforts to reduce or prevent such exposures. To that end, grants of up to $400,000 over up to two years will be awarded in support of investigations
into environmental factors. Applications should focus on studies that achieve the following goals: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Analyze large epidemiological datasets to identify environmental risk factors, such as exposure to chemicals, toxic emissions, air pollutants, and dietary
contaminants, which are associated with an increased risk of PD.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">MJFF is especially interested in funding projects that utilize large longitudinal datasets and will prioritize collaborative efforts that bring together
teams of investigators with access to multiple diverse datasets.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This program is not appropriate for studies that require additional or prospective data collection.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-proposal due May 14, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: May 4.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-154.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFqiUQsEc$" target="_blank">Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely
or via mHealth (R01 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness
of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research
staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility
of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety
of the intervention; and evidence that the intervention has promise of clinical benefit.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-155.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVF1plwsuo$" target="_blank">Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic
technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application
to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related)
problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones
that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance
in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-156.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFnEfDvgs$" target="_blank">Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development
for Alzheimer’s Disease (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by
developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-20-160.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFcsCvC0M$" target="_blank">Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial
Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement encourages the submission of
<b>pilot and feasibility</b> <b>clinical trials</b> conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small,
short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should
have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trialsto improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential
to impact clinical practice and/or public health. <b>Preliminary data regarding intervention efficacy are not required.</b><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer’s Dementia (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-159.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFRkS2e_8$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-157.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFi6DvmwU$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS)
in persons with Alzheimer’s disease (AD) or Alzheimer’s disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into
novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-150.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFv_tKZ-M$" target="_blank">NIMHD Exploratory/Developmental Research Grant Program (R21 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health
disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires June 17, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-20-146.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVF_xqXAcI$" target="_blank">NIDA Small Research Grant Program (R03 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of
projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research
methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-153.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFD7sio1Y$" target="_blank">NIH Science Education Partnership Award (SEPA) (R25)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers.
The over-arching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (2) encourage individuals from diverse backgrounds, including those from
groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical
sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications. The SEPA program supports P-12 and informal science education (ISE) activities that: (1) enhance the diversity of the biomedical, behavioral
and clinical research workforce and (2) foster a better understanding of NIH-funded biomedical, behavioral and clinical research and its public health implications. The SEPA program targets two primary audiences: (1) SEPA formal or classroom-based projects,
provide STEM content, pedagogical expertise, and problem solving skills to teachers, students, and families in communities not generally supported by advanced and innovative educational practices: (2) SEPA ISE activities, conducted in outside-the-classroom
venues as well as in science centers and museums, target both workforce diversity and improved public health literacy. Applications that target pre-kindergarten to grade 12 (P-12) or ISE topics that are not being addressed by existing school, community, or
ISE-based activities are encouraged. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish
the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo6"><b><span style="font-size:12.0pt;font-family:Palatino">Courses for Skills Development</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><b><span style="font-size:12.0pt;font-family:Palatino">Research Experiences</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><b><span style="font-size:12.0pt;font-family:Palatino">Mentoring Activities</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><b><span style="font-size:12.0pt;font-family:Palatino">Curriculum or Methods Development
</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo6"><b><span style="font-size:12.0pt;font-family:Palatino">Outreach</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 14, 2020; July 13, 2021; and July 13, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for July 14, 2020 deadline: July 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-158.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFQ202Ayk$" target="_blank">Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection
by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent
upon achieving negotiated “Go/No-Go” criteria by the end of Year 2.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 28, 2020; July 28, 2021; and July 28, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for July 28, 2020 deadline: July 15.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-024.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFXmYlw-Y$" target="_blank">Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61 / R33 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis and
viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 28, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: July 15.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/lcrp__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFqhDJQDA$" target="_blank">Lung Cancer Research Program</a><br>
<b>Career Development Award</b><br>
Pre-application (required letter of intent): July 15, 2020. Application: July 29, 2020.<br>
<b>Clinical Translational Research Partnership Award</b><br>
Pre-application (required letter of intent): July 15, 2020. Application: July 29, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive pre-application draft documents: July 6.</span></b><b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/nfrp__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFPvbKjFE$" target="_blank">Neurofibromatosis Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020.<br>
<b>Exploration – Hypothesis Development Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020.<br>
<b>New Investigator Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020.<br>
<b>Early Investigator Research Award</b><br>
Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020. Confidential letters of recommendation: July 14, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive pre-application draft documents: June 15.</span></b><b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/prcrp__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFTGNweKk$" target="_blank">Peer Reviewed Cancer Research Program</a><br>
<b>Virtual Cancer Center Director Award</b><br>
Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020.<br>
<b>Career Development Award – Fellow Option</b><br>
Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020.<br>
<b>Career Development Award – Virtual Cancer Center Scholar Option</b><br>
Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive pre-application draft documents: July 20.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Idea Award</b><br>
Pre-application (preproposal): May 14, 2020. Invited full application: August 27, 2020.<br>
<b>Impact Award</b><br>
Pre-application (preproposal): May 14, 2020. Invited full application: August 27, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive pre-application draft documents: May 4.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Behavioral Health Science Award</b><br>
Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020.<br>
<b>Translational Team Science Award</b><br>
Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive pre-application draft documents: July 20.</span></b><b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21 / R01 – Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-148.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFFgUNlq0$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-147.html__;!!PhOWcWs!hg2yUZ4IohnrzY07OLTrmrJeugr5LkQkIT6PFQ8WuRsMMYY3IzEJD-iDuPOMyYC5ea2XNSRaGCVFsMYSxk0$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these FOAs is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders and/or
HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Non-AIDs Due October 13, 2020; March 15, 2021; October 13, 2021; March 15, 2022; October 13, 2022; and March 15, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 13, 2020 deadline: September 30.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">AIDS Due January 7, 2021; May 7, 2021; January 7, 2022; May 7, 2022; January 7, 2023; and May 7, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for January 7, 2021 deadline: December 18, 2020.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
</div>
</body>
</html>